Full Study Title: Open label randomised controlled trial (RCT) of intensive surveillance vs. standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer
- The SARONG study is a multi-centre, open-label, two-arm, parallel design, superiority Randomised Controlled Trial.
- The study aims to determine whether intensive surveillance after completing curatively intended treatment improves survival and health-related quality of life in patients with oesophageal or gastric cancer.
- The SARONG study will recruit adults (aged 16 years or over) receiving surgical resection for curatively intended treatment of oesophageal or gastric cancer with or without neoadjuvant/adjuvant chemo(radio)therapy/ immunotherapy.
- Participant will be randomised to either standard of care or intense surveillance intensive surveillance (including radiological scans (chest and abdomen) and clinical review) every 6 months for 36 months post-randomisation along with an endoscopy at 12 months post-randomisation.
Why do we need a RCT in oesophageal and gastric cancer surveillance?
Open configuration options
- Currently, national or international guidelines do not provide a routine surveillance for the detection of recurrent disease in patients without symptom or evidence of residual disease after treatment for oesophago-gastric cancer with curative intent (NICE guidelines).
- There has yet to be a randomised controlled trial that has compared survival between oesophago-gastric cancer patients undergoing different surveillance protocols.
- There is considerable interest in the oesophago-gastric cancer community in pursuing this.
